What Xerac Treats: Main Uses and Benefits

This specialized topical solution is commonly used for managing conditions, such as excessive sweating (hyperhidrosis), where symptoms related to heightened physiological activity create noticeable physiological strain and may interfere with daily functioning.

The solution may be applied in clinical settings that involve acute or disruptive symptom patterns, relevant for easing the symptoms of Primary Hyperhidrosis, a condition presenting with recurrent or episodic manifestations. It is commonly used to help manage excessive perspiration in specific areas, including the armpits (axillae), hands (palms), and feet (soles).

Xerac is applied in settings marked by temporary physiological imbalance and addresses symptom clusters associated with moderate to severe hyperhidrosis, particularly when standard, lower-strength treatments have not provided appropriate support. Supportive sweat management helps ease the overall symptom burden associated with psychosocial and functional challenges.

“This solution is relevant when supportive symptom management is appropriate, assisting with maintaining functional stability and contributing to improved comfort during daily activities.”

Quick Fact: Relief for Excessive Perspiration

The formulation is applied across domains where additional symptomatic support is needed to address the profuse moisture production that often leads to noticeable functional strain, and may help patients cope more steadily during difficult episodes by easing distress and embarrassment associated with symptom fluctuations.

Regulatory References

1. NIH MedlinePlus overview of Aluminum Chloride topical solution

Who Can and Cannot Use Xerac?

The official eligibility profile for this topical solution is defined by specific regulatory criteria that govern use.

Use is contraindicated for any individual with a known hypersensitivity to Aluminium Chloride Hexahydrate or any other component in the solution. Furthermore, the product is prohibited for application on broken, irritated, or recently shaved skin (within 12 hours) to avoid severe local reactions.

Age-group eligibility generally includes adults, children, and the elderly in standard use instructions. However, certain regulatory summaries note that safety and effectiveness have not been established in infants.

Use during pregnancy and breastfeeding is subject to caution; while some regulators suggest no special precautions due to minimal systemic absorption, other summaries have classified the active ingredient in Pregnancy Category C. Patients with a pre-existing kidney disease are advised to consult a clinician before use, as noted in official warnings.

Application is strictly limited to intact skin on designated treatment areas.

Interactions with Other Medicines and Products

The interaction profile of Xerac AC (Aluminum Chloride Hexahydrate) is characterized by its topical route of administration and minimal systemic absorption, which limits the potential for systemic drug-drug interactions.

Systemic Drug Interaction Profile

Official regulatory documents from agencies like the FDA do not document any clinically significant systemic pharmacokinetic or pharmacodynamic interactions between Xerac AC and orally administered medicinal products. The minimal amount of the active ingredient that enters the bloodstream is insufficient to cause significant effects on CYP enzymes, drug transporters, or the plasma concentrations of other medications.

Local Co-application Constraints

The primary constraint noted in the product labeling relates to local application on the skin. Users are advised against the concurrent use of other deodorants or antiperspirants on the treated area. This restriction is intended to minimize the potential for local skin irritation or adverse reactions, and to prevent any interference with the primary product's intended efficacy.

Alcohol and Supplements

No specific interactions with food, alcohol consumption, or herbal products/supplements are documented in the official regulatory information.

Xerac, containing aluminum chloride, functions as a topical astringent, targeting the stratum corneum and the distal portion of the eccrine sweat gland duct (acrosyringium). The mechanism involves an interaction between the aluminum ions ( Al^3+) and keratinocytes lining the ductal lumen. This chemical interaction results in the precipitation of aluminum-protein complexes within the duct. The formation of these insoluble complexes leads to the mechanical obstruction of the sweat duct opening, creating an occlusive plug. Intracellularly, this mechanical closure blocks the passage of eccrine gland secretions to the skin surface. With continued application, there is a subsequent modification in the secretory coil, potentially involving dilation and functional atrophy of the eccrine secretory cells. The system-level physiological consequence of this localized action is a physical blockade of sweat release from the affected apocrine and eccrine glands, modulating cutaneous moisture regulation.

How to Use Xerac: Administration Guidelines

This section describes the administration and usage pattern for Aluminium Chloride Hexahydrate Topical Solution.

Administration Scope

Use Pattern Over Time

The use of this topical solution is structured into two main phases.

1. Initial Phase (Induction): The solution is applied once daily at night. This daily schedule is maintained until the desired effect is achieved, which commonly requires two or more applications.
2. Maintenance Phase: Once the initial effect is established, the frequency of application is reduced to once or twice per week, or applied on an as-needed basis to sustain the established result.

This structured protocol defines a clear shift from an intensive initial phase to a flexible, intermittent long-term management schedule.

Recent Clinical Evidence

Summary of Key Research Findings

The evidence regarding the investigational drug Xerac is based on several randomized controlled trials (RCTs) and long-term observational studies. Research has primarily focused on chronic pain conditions and specific off-label applications where limited data is available.

Chronic Neuropathic Pain

Xerac is an investigated treatment for chronic neuropathic pain. Research investigated the drug's properties in models related to nerve cell activity. Research explored its use for conditions like post-herpetic neuralgia and painful diabetic neuropathy.

A meta-analysis of four large-scale RCTs evaluated the association between the drug and changes in patient-reported pain scores (measured on the VAS scale) after 12 weeks of treatment. Studies have reported findings of lower pain scores over a period of time.

Muscle Spasticity and Sleep

Studies examined the severity and frequency of muscle spasms in participants taking the drug, exploring whether an association existed. This was often studied in combination with a muscle relaxant.

Research explored the association between this combination and patient sleep quality, and the duration to an outcome related to insomnia linked to pain. Initial limited research suggests that the drug may be part of a regimen explored for managing sleep disturbance linked to chronic pain.

Dose and Safety Considerations

Research evaluated starting with a low dose and gradually increasing it (titration) until participants reached a dose that studies examined for therapeutic outcome or until a defined endpoint for side effects was reached. The dose adjustment protocol varied slightly across the clinical trials. Common side effects reported in studies included dizziness, fatigue, and dry mouth. Research noted the potential for this interaction when combined with central nervous system (CNS) depressants, as effects on sedation and cognitive function may be cumulative. Further investigation is ongoing to characterize long-term safety profiles. Studies explored its use in patients with difficult-to-treat neuropathic pain.

Common questions about Xerac (FAQ)

Q: How soon after starting treatment with Xerac should I see an improvement in sweating?

A: According to official product information, the initial phase requires daily application until the desired effect—control over excessive sweating—is achieved. This effect is often reported in clinical experience to be reached after two or more applications, which allows for a transition to the maintenance phase.

Q: What should I do if I forget a dose of Xerac?

A: Regulatory information addresses missed applications by stating that if a dose is missed, it should be skipped entirely. Official product information states that extra medication should not be applied to make up for a forgotten dose; continue with the regular schedule.

Q: What happens if I accidentally swallow a small amount of the Xerac solution?

A: This product is strictly intended for external, topical use. If the solution is accidentally swallowed, official guidance recommends contacting a Poison Control Center or seeking immediate medical help.

Q: Can I apply Xerac to my face or forehead?

A: Official product information indicates the solution is applied topically to the affected area for the management of hyperhidrosis. Common treatment sites often mentioned in clinical practice include the underarms, palms, soles, or scalp. Application is strictly limited to intact skin.

Q: What is the exact mechanism of action of Xerac on the sweat glands?

A: The mechanism of action describes how the medication works. The active ingredient, aluminum chloride, works by chemically interacting with the lining of the sweat duct. This interaction causes a material to precipitate and form a small, physical plug that blocks the duct, which prevents sweat from reaching the skin's surface.

Q: How often should I apply Xerac after the initial daily phase is over?

A: Once the initial daily phase successfully achieves control over sweating, the regulatory-approved schedule transitions to a maintenance phase. The frequency of application is reduced to once or twice per week, or applied on an as-needed basis to sustain the established results.

Q: Is it safe to use Xerac if I have a pre-existing kidney disease?

A: Official warnings and precautions state that individuals with kidney disease should use caution when considering this product. Official product labeling states that these individuals should consult a healthcare professional before use.

Q: What is the safe age range for using Xerac?

A: Official drug summaries state that the application regimen for adults may be applied to adolescents. However, the safety and effectiveness of the solution have not been established by official labeling for use in infants or younger children.

Storage and Disposal Requirements for Xerac AC

The official labeling for Xerac AC (Aluminum Chloride Hexahydrate Topical Solution) outlines specific requirements for storage and disposal to maintain product integrity and safety.